Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

Journal of Rheumatology

Volumn 37, Issue 3, 2010, Pages 558-567

  Van Vollenhoven, Ronald F ^a   Emery, Paul ^b   Bingham III, Clifton O ^c   Keystone, Edward C ^d   Fleischmann, Roy ^e   Furst, Daniel E ^f   Macey, Katherine ^g   Sweetser, Marianne ^h   Kelman, Ariella ⁱ   Ravi, Rao ^g  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ROCHE PRODUCTS LTD   (United Kingdom)

^h BIOGEN   (United States)

ⁱ GENENTECH INC   (United States)

Author keywords

Clinical trials; Rheumatoid arthritis; Rituximab

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; PLACEBO; RITUXIMAB;

ABSCESS; ADULT; ANGINA PECTORIS; ARTICLE; BRONCHITIS; BRONCHOPNEUMONIA; BUERGER DISEASE; CANCER INCIDENCE; CARDIOVASCULAR RISK; CELLULITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GANGRENOUS CELLULITIS; GASTROENTERITIS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART TAMPONADE; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HYPERTENSION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFUSION RELATED REACTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OROPHARYNX CANCER; PERICARDITIS; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK ASSESSMENT; SINUSITIS; THROMBOSIS; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 77949673916     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090856     Document Type: Article

References (40)

1. Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005;32:1232-42.
2. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051.
3. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
4. Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009;38:265-80.
5. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
6. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003;42:617-21.
7. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
8. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11.
9. Khan AH, Spodick DH. Rheumatoid heart disease. Semin Arthritis Rheum 1972;1:327-37.
10. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
11. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
12. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
13. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908.
14. Sell S, Max EE. All about B cells. In: Immunology, immunopathology, and immunity. Herndon, VA: ASM Press; 2001:101.
15. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
16. Emery P, Rigby WF, Combe B, Latinis K, Szczepanski LJ, Roschmann RA, et al. Efficacy and safety of rituximab (RTX) as first line biologic therapy in patients with active rheumatoid arthritis. Results of a phase III randomized, controlled study (SERENE) [abstract]. Arthritis Rheum 2008;Suppl 58:S302.
17. Rubbert-Roth A, Tak PP, Bombardieri S, Zerbini C, Tremblay J, Carreño L, et al. Efficacy and safety of various dosing regimens of rituximab in patients with active RA: results of a phase III randomized study (MIRROR) [abstract]. Arthritis Rheum 2008;Suppl 58:S301.
18. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, et al. Efficacy, safety, and dose frequency of retreatment with rituximab in RA: results from a randomized controlled trial (SUNRISE) [abstract]. Arthritis Rheum 2008;Suppl 58:S619.
19. Bingham C, Looney R, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Results from a controlled clinical trial (SIERRA) to evaluate primary and recall responses to immunizations in RA patients treated with rituximab [abstract]. Arthritis Rheum 2008;Suppl 58:S900.
20. Keystone EC, Fleischmann R, Emery P, Chubick A, Dougados MR, Baldassare AR, et al. Efficacy and safety of repeat treatment courses of rituximab (RTX) in RA patients with inadequate response to tumor necrosis factor inhibitors; long-term experience from the REFLEX study [abstract]. Arthritis Rheum 2008;Suppl 58:S303.
21. Centers for Disease Control/National Center for Health Statistics. National Vital Statistics Reports. Deaths: Final data for 2005. [Internet. Accessed Dec 10, 2009.] Available from: http://www.cdc.gov/nchs/data/nvsr/ nvsr56/nvsr56-10.pdf
22. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61.
23. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-54.
24. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-63.
25. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology 2006;45:1370-5.
26. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431-8.
27. Aksamit AJ. Progressive multifocal leukoencephalopathy. Curr Treat Options Neurol 2008;10:178-85.
28. Rahmlow M, Shuster EA, Dominik J, Deen HG Jr, Dickson DW, Aksamit AJ Jr, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol 2008;65:1538-9.
29. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008;8:144-6.
30. Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007;56:3909-18.
31. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94(5 Suppl 1):S1-63.
32. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88.
33. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63:395-400.
34. Burns EA, Lum LG, L'Hommedieu G, Goodwin JS. Specific humoral immunity in the elderly: in vivo and in vitro response to vaccination. J Gerontol 1993;48:B231-6.
35. Dixon WG, Watson KD, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12.
36. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12.
37. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller M, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
38. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9.
39. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
40. Burmester GR, Mariette X, Montecucco C, Monteagudo-Sáez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66:732-9.